Colgate-Palmolive Company CL stock is in investors’ good books, thanks to its robust business strategies. The pricing and productivity initiatives have been driving the company’s performance for a while now. Its innovation strategy and shareholder-friendly moves also bode well. Shares of this renowned consumer goods company have gained 31.9% in the past year compared with the industry’s 15.8% growth. Let’s Find Out More Colgate has been gaining from strong pricing and the benefits of funding-the-growth program and other productivity initiatives. The company has been implementing aggressive pricing for a while now, which boosted margins in the first quarter of 2024. The gross margin expanded 310 basis points to 60% on both GAAP basis and adjusted basis. As a result, adjusted basis earnings advanced 18% from the prior-year period. Zacks Investment Research Image Source: Zacks Investment Research Additionally, the company’s innovation strategy is focused on growing in adjacent categories and product segments. It is focused on the premiumization of its Oral Care portfolio through major innovations. Backed by premium innovation, products including CO. by Colgate, Colgate Elixir toothpaste and Colgate enzyme whitening toothpaste have been performing well. Also, at-home whitening and professional whitening products bode well. The company’s Oral Care business has also been performing well. Some other notable efforts include the continued expansion of the Naturals and Therapeutics divisions as well as the Hello Products LLC buyout. Regarding its shareholder-friendly efforts, Colgate is committed to rewarding shareholders with share buybacks and dividend payouts. Recently, it paid a dividend of 50 cents a share. On an annualized basis, the dividend rate is $2.00, up from $1.92 per share paid previously. Markedly, the company has paid uninterrupted dividends since 1895. Bottlenecks to Growth Colgate has been witnessing inflationary pressures and a tough macroeconomic environment for quite some time now. Raw material inflation and the continued rise in packaging also act as a deterrent to the company’s profitability. In addition, it has been witnessing continued volume softness in China and the headwind from lower private label growth as it transferred more of Hill’s volume into the pet nutrition manufacturing network. Foreign currency fluctuations are also acting as headwinds. The sales view for 2024 includes a mid-single-digit negative impact of currency compared with a low-single-digit negative impact expected earlier. Final Thoughts Nevertheless, Colgate has been making prudent initiatives to maneuver the aforesaid challenges. In addition, the accelerated revenue-growth management plans have been bolstering the company’s sales. Analysts seem optimistic about the company. The Zacks Consensus Estimate for 2024 sales and earnings per share (EPS) is currently pegged at $20.2 billion and $3.53, respectively, indicating growth of 3.9% and 9.3%. A Growth Score of A further adds strength to this Zacks Rank #2 (Buy) company. Other Stocks to Consider Freshpet FRPT, a pet food company, currently sports a Zacks Rank #1 (Strong Buy). FRPT has a trailing four-quarter earnings surprise of 118.2%, on average. You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Freshpet’s current financial-year sales and EPS indicates growth of 24.8% and 177.1%, respectively, from year-ago reported numbers. Vital Farms Inc. VITL offers a range of produced pasture-raised foods. It currently sports a Zacks Rank of 1. VITL has a trailing four-quarter average earnings surprise of 102.1%. The consensus estimate for Vital Farms’ current financial-year sales and EPS indicates growth of 22.6% and 62.7%, respectively, from the year-ago reported numbers. Utz Brands Inc. UTZ, which manufactures a diverse portfolio of salty snacks, currently carries a Zacks Rank of 2. UTZ has a trailing four-quarter earnings surprise of 2%, on average. The Zacks Consensus Estimate for Utz Brands’ current financial-year EPS indicates growth of 26.3% from the year-ago reported numbers. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Colgate-Palmolive Company (CL):Free Stock Analysis Report Freshpet, Inc. (FRPT):Free Stock Analysis Report Vital Farms, Inc. (VITL):Free Stock Analysis Report Utz Brands, Inc. (UTZ):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Colgate's (CL) Innovation & Pricing Efforts Aid: Apt to Buy?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...